Table 3.

Characteristics of Guillain-Barré Syndrome (GBS) patients with antecedent CMV infection (N = 18) and non-CMV infections (N = 107), MarketScan 2009–2015^a

Variable	Persons with GBS and CMV N=18		Persons with GBS and non-CMV Infections (Campylobacter, Epstein-Barr virus, hepatitis E, influenza, Mycoplasma pneumoniae) N=107		p-valued
Year	#	%	#	%
2009	2	11.1%	22	20.6%
2010	1	5.6%	9	8.4%
2011	4	22.2%	17	15.9%
2012	4	22.2%	14	13.1%
2013	5	27.8%	11	10.3%
2014	1	5.6%	15	14.0%
2015	1	5.6%	19	17.8%
Age group (years)
0–17	2	11.1%	21	19.6%
18–34	5	27.8%	28	26.2%
35–44	5	27.8%	16	15.0%
34–54	1	5.6%	13	12.1%
55–64	4	22.2%	21	19.6%
≥65	1	5.6%	8	7.5%
Gender					1.0000
Female	10	55.6%	54	50.5%
GBS-related proceduresb
Lumbar puncture	15	83.3%	91	85.0%	0.713
EMG or NCS	13	72.2%	63	58.9%	0.278
GBS Severity/Outcomes
Dysautonomiac	1	5.6%	3	2.8%	1.000
ICU Hospitlization	9	50.0%	58	54.2%	0.793
Intubation	5	27.8%	17	15.9%	0.473
Died	1	5.6%	0	0.0%	0.130
Median Duration of Hospitalization (range), in days	7 (1–38 days)		7 (0–34 days)		0.811

^aThere were a total of 125 GBS cases with an antecedent infection with a specific pathogen identified. Two of the 125 GBS cases had claims for both CMV and EBV and are included in the frequencies of persons with GBS and CMV.

^bGBS-related procedures that occurred within −45 to 45 days of GBS onset date.

^cProportion of persons with dysautonomia among persons enrolled over the 14-month interval ranging from 2 months before through 12 months after GBS onset date (N = 2,105, 180 in persons aged <18 years and 1,925 in persons aged ≥18 years).

^dStatistical analysis excludes the 2 GBS cases with both CMV and EBV from the comparison of GBS patients with and without CMV.